Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 17/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 14/20 | 0.43 |
| ▸ | PGR | P06401 | 6/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21656177 | 0.91 | MTNR1A (0.40) | NR3C1NR3C2PGRMTNR1AMTNR1B | |
| SCHEMBL21632105 | 0.86 | NR3C1 (0.46) | NR3C1NR3C2PGR | |
| SCHEMBL21656175 | 0.84 | MTNR1A (0.41) | MTNR1AMTNR1B | |
| SCHEMBL21656334 | 0.81 | MTNR1A (0.38) | NR3C1NR3C2PGRMTNR1AMTNR1B | |
| SCHEMBL21708649 | 0.81 | NR3C1 (0.39) | NR3C1NR3C2PGR | |
| SCHEMBL21656201 | 0.80 | NR3C1 (0.41) | NR3C1NR3C2MTNR1AMTNR1B | |
| SCHEMBL21656108 | 0.79 | MTNR1A (0.40) | NR3C2MTNR1AMTNR1B | |
| SCHEMBL21631931 | 0.77 | NR3C2 (0.42) | NR3C1NR3C2PGR | |
| SCHEMBL31445000 | 0.73 | NR3C1 (0.47) | NR3C1NR3C2PGR | |
| SCHEMBL4490249 | 0.73 | NR3C2 (0.51) | NR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | NR3C1 548/4885NR3C2 362/4885PGR 3438/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | NR3C1 548/4885NR3C2 362/4885PGR 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.